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Objective: To investigate the optimal timing of direct acting antiviral (DAA)
administration in patients with hepatitis C-associated hepatocellular carcinoma (HCC) undergoing liver transplantation (LT).
Summary of Background Data: In patients with hepatitis C (HCV) associated HCC undergoing LT, the optimal timing of direct-acting antivirals (DAA)
administration to achieve sustained virologic response (SVR) and improved
oncologic outcomes remains a topic of much debate.
Methods: The United States HCC LT Consortium (2015–2019) was
reviewed for patients with primary HCV-associated HCC who underwent
LT and received DAA therapy at 20 institutions. Primary outcomes were SVR
and HCC recurrence-free survival (RFS).
Results: Of 857 patients, 725 were within Milan criteria. SVR was associated
with improved 5-year RFS (92% vs 77%, P < 0.01). Patients who received
DAAs pre-LT, 0–3 months post-LT, and 3 months post-LT had SVR rates of
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91%, 92%, and 82%, and 5-year RFS of 93%, 94%, and 87%, respectively.
Among 427 HCV treatment-naı̈ve patients (no previous interferon therapy),
patients who achieved SVR with DAAs had improved 5-year RFS (93% vs
76%, P < 0.01). Patients who received DAAs pre-LT, 0–3 months post-LT,
and 3 months post-LT had SVR rates of 91%, 93%, and 78% (P < 0.01) and
5-year RFS of 93%, 100%, and 83% (P ¼ 0.01).
Conclusions: The optimal timing of DAA therapy appears to be 0 to 3 months
after LT for HCV-associated HCC, given increased rates of SVR and improved
RFS. Delayed administration after transplant should be avoided. A prospective
randomized controlled trial is warranted to validate these results.
Keywords: direct acting antivirals, hepatitis C, hepatocellular carcinoma,
liver transplant, recurrence, sustained virologic response
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epatitis C virus (HCV) is the most common cause of hepatocellular carcinoma (HCC) in the United States, affecting 6 per
100,000 individuals each year.1 Between 2008 and 2016, the incidence rate of HCC has steadily increased by 3% annually, with recent
projections indicating its continued growth.2 This is partly attributable to the high prevalence of HCV.3
Historically, the mainstay of treatment for HCV included
interferon-based regimens with or without ribavirin. Given a significant adverse drug reaction profile, this regimen had poor adherence,
as well as low overall rates of achieving a sustained virologic
response (SVR), defined as no detectable virus 12 to 24 weeks after
end of therapy.4 Fortunately, the advent of direct acting antivirals
(DAAs) in 2011 and subsequent U.S. Food and Drug Administration
approval of second generation DAAs in 2014 revolutionized the
treatment of HCV by offering a well-tolerated and much more
efficacious treatment option, with a favorable side-effect profile,
which resulted in improved compliance and rates of SVR exceeding
95%.4
Chronic HCV infection leads to hepatic inflammation and
fibrosis, conferring an over 20-fold increased risk for developing
HCC.5 DAAs halt HCV’s continuous insult on the liver and may
improve liver function, potentially reducing the risk for developing
de novo HCC.6,7 However, some studies have suggested DAA
administration was associated with increased rates of HCC recurrence after curative treatment of HCC.8,9 On the other hand, recent
larger and well-controlled studies found no significant difference in
HCC recurrence in DAA-treated patients, and multicenter studies
from both the US and Asia have shown significant survival improvement in HCC patients with HCV cure.10–12
For cirrhotic patients with early-stage HCC within Milan
criteria, liver transplantation (LT) remains the gold-standard curative
treatment option.13 In the US, an estimated 900 liver transplants are
performed each year for HCV-associated HCC.14 In light of controversial data suggesting DAAs may accelerate HCC recurrence and
the paucity of data investigating the impact of timing of DAAs in the
setting of LT, there is significant practice pattern variability across
the country for when DAAs are administered, either pre or post-LT.
Thus, we sought to assess the optimal timing of DAAs in patients
with HCV-associated HCC who underwent LT.

METHODS
Study Design and Study Population
In this retrospective cohort study, patients were selected from
the US Hepatocellular Carcinoma Liver Transplantation Consortium
(US-HCC-LTC), a multi-institutional collaborative of 20 high-volume liver transplant centers, including Emory University, the University of Cincinnati College of Medicine, David Geffen School of
Medicine at University of California Los Angeles, Johns Hopkins,
Oregon Health and Science University, Indiana University Health,
University of Alabama at Birmingham, Lahey Hospital and Medical
Center, Keck Hospital of University of Southern California, Cleveland Clinic, University of Texas Southwestern Medical Center,
Stanford University Medical Center, Tampa General Hospital, Piedmont Healthcare, University of Michigan, University of Wisconsin
School of Medicine in Madison, Duke University School of Medicine, Henry Ford Health System, University of Pittsburgh Medical
Center, and Washington University School of Medicine in St. Louis.
Patients who were older than 18 years of age with a diagnosis of HCC
due to HCV etiology, received DAA therapy, and underwent LT
between 2015 and 2019 were included. HCC diagnosis was made
according to the established Barcelona Clinic Liver Cancer Guidelines. HCV diagnosis was defined by the presence of HCV antibody
or HCV RNA. Patients who had missing DAA timing data, who had
614 | www.annalsofsurgery.com

gross residual disease at the time of surgery (R2), who were transplanted outside of Milan criteria, or who previously received interferon therapy were excluded from final analysis. Institutional Review
Board approval was obtained at each center before the initiation of
data collection.

Study Variables and Outcomes
Demographic, preoperative, operative, postoperative, histopathologic, and long-term survival outcomes were collected via
review of each patient’s electronic medical record. DAA therapy
timing was categorized as the initiation of DAA therapy pre-LT, 0 to
3 months post-LT, or 3 months post-LT. Liver-directed therapy
included radiofrequency ablation, transarterial chemoembolization,
and/or Y-90. Primary outcomes were SVR and HCC recurrence-free
survival (RFS). Acute rejection included acute T-cell mediated
(cellular) rejection or acute antibody-mediated rejection.

Analytic Plan
Statistical analysis was conducted with SPSS 26.0 software
(IBM Inc, Armonk, NY). Descriptive statistics for each variable are
reported. A significance level (alpha) of 0.05 was specified for twotailed tests. Comparative analysis was performed, including Chisquared tests or Fisher exact tests for discrete variables and Student t
test or Mann-Whitney tests for continuous variables. Univariate
binary logistic regression was performed to determine the association
of clinicopathologic variables and outcomes of interest. KaplanMeier log-rank analysis and Cox regression were performed to
determine the association between timing of DAA therapy and
HCC RFS.

RESULTS
Study Cohort Characteristics
Of the 857 patients in the US-HCC-LTC, 427 met the specified
inclusion criteria. Baseline demographic, clinicopathologic, perioperative, and oncologic data are outlined in Table 1. Fifty-eight
percent (n ¼ 258) of patients received DAAs pre-LT, 10% (n ¼
45) received DAAs 0 to 3 months post-LT, and 27% (n ¼ 124)
received DAAs 3 months post-LT. The median age at diagnosis was
61 years. A higher proportion of patients received ledipasvir/sofosbuvir compared to a sofosbuvir/velpatasvir or glecaprevir/pibrentasvir regimen. Although the majority of patients underwent liverdirected therapy before LT, a higher proportion received liverdirected therapy if DAAs were administered pre-LT (93%, n ¼
241), compared to those who received DAAs 0 to 3 months postLT (89%, n ¼ 40) or 3 months post-LT at (82%, n ¼ 102). Patients
who received DAAs post-LT were more likely to receive an HCVþ
donor liver, with 36% (n ¼ 16) of patients receiving HCVþ livers in
the 0 to 3 months post-LT group and 33% (n ¼ 40) in the 3 months
post-LT group, compared to 4% (n ¼ 9) in the pre-LT group. Notably,
postoperative complication rates did not differ between the DAA
timing groups (42% pre-LT, 53% 0–3 months post-LT, 48%
3 months post-LT, P ¼ 0.25). A higher rate of acute rejection
was seen in the patients who received DAAs 0 to 3 months post-LT
(27%, n ¼ 12), compared to those who received DAAs pre-LT (13%,
n ¼ 34) and 3 months post-LT (8%, n ¼ 10). The median time on
the waitlist was 7 months (interquartile range, IQR 3–12). Median
follow-up from liver transplant was 36 months (IQR 21–52).

Sustained Virologic Response
For patients within Milan criteria who were interferon-treatment naı̈ve, receiving DAA therapy 3 months post-LT was associated with a decreased odds of achieving SVR (OR 0.36, 95% CI
0.20–0.65, P < 0.01) (Table 2). Patients who received DAAs pre-LT,
ß
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TABLE 1. Baseline Characteristics for Interferon-naı̈ve Patients With HCV-associated HCC Within Milan Criteria Who Underwent
Liver Transplantation
Variable
Age at diagnosis (median, IQR)
Sex
Female
Male
Race/Ethnicity
White
Black
Asian
Latino
Other
ASA
I
II
III
IV
Functional status
Independent
Partially dependent
Totally dependent
DAA regimen
Sofosbuvir/velpatasvir
Ledipasvir/sofosbuvir
Glecaprevir/pibrentasvir
Other
SVR achieved
No
Yes
Received liver-directed therapy
No
Yes
Deceased donor
Deceased donor
Living donor
HCVþ donor liver
No
Yes
Any postoperative complication
No
Yes
Acute rejection
No
Yes
Re-transplant
No
Yes
Months on waitlist (median, IQR)
Follow-up in months (median)

All Patients

Pre-LT

0–3 months Post-LT

3 mo Post-LT

n ¼ 427 (%)

n ¼ 258 (58)

n ¼ 45 (10)

n ¼ 124 (27)

P value

61 (57–65)

61 (57–66)

62 (60–66)

61 (57–64)

0.60
0.70

85 (20)
342 (80)

54 (21)
204 (79)

7 (16)
38 (84)

24 (19)
100 (81)

273 (64)
72 (17)
14 (3)
64 (15)
4 (1)

160 (62)
45 (17)
11 (4)
41 (16)
1 (1)

27 (61)
10 (22)
0 (0)
7 (16)
1 (1)

86
17
3
16
2

(69)
(14)
(2)
(13)
(2)

1 (1)
21 (5)
141 (33)
256 (61)

1 (1)
19 (8)
79 (31)
151 (60)

0
0
19
26

0
2
43
79

(0)
(2)
(35)
(63)

304 (75)
91 (23)
9 (2)

185 (76)
55 (23)
3 (1)

23 (62)
12 (33)
2 (5)

96 (78)
24 (19)
4 (3)

32 (8)
240 (57)
44 (10)
104 (25)

17 (7)
155 (62)
0 (0)
79 (31)

2 (4)
22 (49)
14 (31)
7 (16)

13
63
30
18

54 (13)
365 (87)

24 (9)
231 (91)

3 (7)
41 (93)

27 (23)
93 (77)

44 (10)
383 (90)

17 (7)
241 (93)

5 (11)
40 (89)

22 (18)
102 (82)

424 (99)
2 (1)

256 (99)
1 (1)

45 (100)
0 (0)

123 (99)
1 (1)

351 (84)
65 (16)

242 (96)
9 (4)

28 (64)
16 (36)

81 (67)
40 (33)

236 (55)
190 (45)

150 (58)
107 (42)

21 (47)
24 (53)

65 (52)
59 (48)

371 (87)
56 (13)

224 (87)
34 (13)

33 (73)
12 (27)

114 (92)
10 (8)

420 (99)
6 (1)
7 (3–12)
36 (21–52)

253 (98)
4 (2)
8 (4–14)
34 (18–51)

44 (98)
1 (2)
7 (2–8)
30 (19–44)

123 (99)
1 (1)
8 (4–7)
41 (28–54)

0.47

0.10

0.17

<0.01
(11)
(51)
(24)
(14)
<0.01
<0.01
0.76
<0.01
0.25
<0.01
0.75

0 to 3 months post-LT, and 3 months post-LT achieved SVR rates of
91%, 93%, and 78%, respectively. Notably, patients who received
DAAs pre and 0 to 3 months post-transplant had nearly a 15%
increased rate of SVR compared to those who received DAAs
3 months post-transplant.
Of the 725 patients within Milan criteria, regardless of prior
HCV treatment, patients who received DAAs pre and 0 to 3 months
post-LT had an increased rate of SVR of 91% and 92%, compared to
82% for those who received DAAs 3 months post-transplant (P <
0.01).

HCC Recurrence-Free Survival
Receiving DAA therapy 3 months post-LT was associated
with worse RFS on univariate Cox regression (HR 2.34, 95% CI
ß

(0)
(0)
(42)
(58)
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<0.01
<0.01

1.14–4.82, P ¼ 0.02) (Table 3). Factors associated with improved
RFS included achieving SVR (HR 0.28, 95% CI 0.13–0.62, P <
0.01) and a ledipadsvir/sofosbuvir DAA regimen (HR 0.33, 95% CI
0.13–0.84, P < 0.01). Prior liver-directed therapy was not associated
with RFS.
Considering patients within Milan criteria who were interferon-treatment naı̈ve, achieving SVR with DAAs was associated
with improved 5-year RFS at 93%, compared to 76% in those who
did not achieve SVR (Fig. 1). Receiving DAAs 0 to 3 months post-LT
was associated with an improved 5-year RFS of 100% compared to
those who received DAAs pre-LT at 93%, and 83% for those who
received DAAs 3 months post-LT (Fig. 2). Administering DAAs in
the early postoperative period (0–3 months) was associated with
improved SVR and RFS.
www.annalsofsurgery.com | 615
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TABLE 2. Univariate Binary Logistic Regression for Achieving
SVR for Interferon-naı̈ve Patients With HCV-associated HCC
Within Milan Criteria Who Underwent Liver Transplantation

TABLE 3. Univariate Cox Regression for Recurrence-free Survival for Interferon-naı̈ve Patients With HCV-associated HCC
Within Milan Criteria Who Underwent Liver Transplantation

Logistic Regression
Age at diagnosis (median, IQR)
Sex
Female
Male
Race/Ethnicity
White
Black
Asian
Latino
ASA
I
II
III
IV
Functional status
Independent
Partially dependent
Totally dependent
DAA regimen
Sofosbuvir/velpatasvir
Ledipasvir/sofosbuvir
Glecaprevir/pibrentasvir
Other
Timing of DAA therapy
Pre-LT
0–3 mo post LT
3 mo post LT
Received liver-directed therapy
No
Yes
Deceased donor
Deceased donor
Living donor
HCVþ donor liver
No
Yes
Any postoperative complication
No
Yes
Acute rejection
No
Yes
Retransplant
No
Yes
Months on waitlist

Cox Regression

OR (95% CI)

P value

1.03 (0.98–1.07)

0.31

Reference
0.46 (0.19–1.11)

0.08

Reference
0.55 (0.27–2.09)
1.74 (0.22–13.75)
1.05 (0.44–2.51)

0.55
1.74
1.05

Reference
–
–
–

–
–
–

Reference
1.18 (0.58–2.40)
1.14 (0.14–9.46)

0.65
0.91

Reference
0.48 (0.11–2.11)
0.24 (0.05–1.18)
0.38 (0.08–1.77)

0.33
0.08
0.22

Reference
1.42 (0.41–4.93)
0.36 (0.20–0.65)

0.58
<0.01

Reference
1.33 (0.56–3.16)

0.52

Reference
–
Reference
0.65. (0.31–1.34)
Reference
0.60 (0.34–1.07)
Reference
1.47 (0.56–3.87)
Reference
–
1.01 (0.99–1.03)

–
0.24
0.08
0.44

0.38

For patients meeting Milan criteria, including those who
received prior HCV treatment, patients who received DAAs preLT, 0 to 3 months post-LT, and 3 months had 5-year RFS of 93%,
94%, and 87%, respectively (P ¼ 0.15).

DISCUSSION
For interferon treatment-naı̈ve patients with HCV-associated
HCC within Milan criteria undergoing LT, our analysis of a large
multi-institutional collaborative of 20 high-volume centers in the US
demonstrates that administering DAAs in the early postoperative
period, specifically within 3 months of LT, is associated with
improved rates of achieving SVR and increased HCC RFS.
Before 2011, treatment for HCV was severely limited, as the
only available option was interferon-based therapy. Unfortunately,
616 | www.annalsofsurgery.com

Age at diagnosis (median, IQR)
Sex
Female
Male
Race/Ethnicity
White
Black
Asian
Latino
Other
ASA
I
II
III
IV
Functional status
Independent
Partially dependent
Totally dependent
DAA regimen
Sofosbuvir/velpatasvir
Ledipasvir/sofosbuvir
Glecaprevir/pibrentasvir
Other
Timing of DAA therapy
Pre-LT
0–3 mo post-LT
3 mo post LT
SVR achieved
No
Yes
Received liver-directed therapy
No
Yes
Deceased donor
Deceased donor
Living donor
HCVþ donor liver
No
Yes
Any postoperative complication
No
Yes
Acute rejection
No
Yes
Retransplant
No
Yes
Months on waitlist

HR (95% CI)

P value

0.99 (0.94–1.05)

0.83

Reference
2.43 (0.74–7.96)

0.14

Reference
1.13 (0.46–2.78)
–
1.11 (0.41–2.89)
–

0.80
–
0.86
–

Reference
1.38 (0.17–10.86)
2.13 (0.29–15.80)
–

0.76
0.46
–

Reference
0.36 (0.11–1.19)
1.83 (0.44–7.71)

0.09
0.41

Reference
0.33 (0.13–0.84)
0.26 (0.05–1.29)
0.21 (0.07–0.71)

<0.01
0.10
<0.01

Reference
–
2.34 (1.14–4.82)

–
0.02

Reference
0.28 (0.13–0.62)

<0.01

Reference
1.49 (0.46–4.90)

0.51

Reference
–

–

Reference
0.82 (0.32–2.14)

0.69

Reference
1.50 (0.76–2.98)

0.25

Reference
1.16 (0.45–3.00)

0.76

Reference
2.89 (0.39–21.19)
0.97 (0.93–1.02)

0.29
0.19

given suboptimal efficacy and significant adverse drug reactions,
interferon was poorly tolerated, leading to poor compliance and
modest SVR rates ranging from 29% to 56%.15,16 The emergence of
DAAs fundamentally changed the HCV treatment landscape by
offering a simple one pill per day dosing with minimal side effects,
allowing patients to achieve SVR rates of 95% to 97%.17 As a result,
patients benefited from marked improvement in liver-associated
morbidity and mortality. A 2017 retrospective review of 22,500
patients with HCV reported achieving SVR with DAAs resulted
in a significantly reduced risk of developing de novo HCC (HR 0.28,
ß
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FIGURE 1. HCC recurrence-free survival by SVR for interferonnaı̈ve patients with HCV-associated HCC within Milan criteria
who underwent liver transplantation.
95% CI 0.22–0.36).18 In addition, a more recent study from our
group demonstrated the association of HCV treatment with improved
long-term outcomes in patients treated for HCC, regardless of
clinical stage, HCC treatment modality, or treatment facility type.19
However, it is important to note that the high SVR rates often quoted
are derived from studies that include patients with HCV who do not
have active HCC. Patients with active HCC seem to achieve significant lower rates of SVR compared to non-HCC patients. In fact, a
recent meta-analysis published in 2019 reported SVR rates with
DAA therapy in the presence of active HCC were as low as 73%.20
The investigators also determined SVR rates were higher in patients
who underwent curative-intent treatments of their HCC before
receiving DAA therapy. Although the exact mechanism for this
observation is not fully understood, HCC may function as a reservoir
for HCV replication. Regardless, with the considerable success of

FIGURE 2. HCC recurrence-free survival by timing of DAA
therapy initiation for interferon-naı̈ve patients with HCV-associated HCC within Milan criteria who underwent liver transplantation.
ß
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DAAs, interferon-based treatment strategies are no longer relevant to
the modern management of HCV. Hence, for this study, we focused
on an interferon treatment-naı̈ve patient population. Furthermore, by
excluding patients with prior interferon therapy, we removed a
potential confounder for the immunologic interaction between
HCV, HCC, and transplant immunosuppression, to better isolate
the DAA timing question.
Considering the multiple treatment approaches for HCC,
complete tumor extirpation, specifically resection or LT, are the
preferred curative treatment options, with the latter resulting in the
most favorable long-term outcomes.21 Although the appropriate
treatment strategy is dependent on the tumor burden, liver function,
renal function, Child-Pugh status, and the future liver remanent, LT
not only allows for clearance of the tumor, but also addresses any
underlying liver disease. Other treatment modalities, including liverdirected therapy, radiation therapy, and systemic therapy, are often
employed in combination with resection or as a bridge to liver
transplant.22 Given patients within Milan criteria are on the waitlist
for an average of 8.4 months, many are offered bridging therapy to
transplant with the goal of preventing disease progression beyond
Milan criteria.23 Predictably, liver-directed therapies are more frequently employed in liver transplant patients compared to other HCC
patients.24 Our data supports this trend. Nonetheless, compared to all
other treatment approaches for unresectable disease, liver transplant
offers superior oncologic outcomes in well-selected patients, with 5year overall survival surpassing 70%.25
Recent reports have described the immunomodulatory effect of
DAAs in the context of HCC and liver transplant. HCV is known to
induce hepatocyte apoptosis, oxidative stress, and steatosis, resulting
in progressive liver damage, fibrosis, and ultimately end-stage liver
disease.26 The 3 main classes of DAAs work by inhibiting specific
HCV nonstructural proteins involved in viral replication, namely NS3/
4A, NS5A, and NS5B.27 Although most do not consider DAAs
themselves tumorigenic, DAAs may increase the risk for de novo
HCC or recurrence via an indirect mechanism. After eradication of the
virus, DAA therapy evokes profound immunological changes. Specifically, DAAs rapidly decrease the cytotoxic function of natural killer
cells and mucosal-associated invariant T cells, dampen intrahepatic
activation of macrophages, and increase frequencies of suppressive
regulatory T cells and myeloid-derived suppressor cells.28 The downstream effects of this are the creation of a persistent immunosuppressed
state with ineffective tumor surveillance mechanisms.
Offering DAA therapy before liver transplant allows for the
treatment of HCV while the patient is on the waitlist, which reduces
chronic hepatitis and may improve liver function.29 Improvements in
liver function due to DAA therapy, however, have not been shown to
significantly impact waitlist priority or dropout rates.30,31 Further,
HCV exposure to the liver transplant surgical team is dramatically
reduced. A potential disadvantage for administering DAA therapy
before liver transplant in the setting of HCC includes decreased rates
of SVR, as the presence of HCC tumors may serve as a reservoir for
HCV.20 This increases the risk for treatment failure and promotes
resistance to re-treatment, which requires additional courses of
DAAs, leading to an excess of $25,000 to 70,000 in costs compared
to those who receive DAAs post-LT.32,33
Conversely, reserving DAA therapy until after liver transplant
may be preferred based on data demonstrating the improved efficacy
of DAAs in achieving SVR, as well as a potential for a decreased risk
of recurrence of HCC.34 Further, treating HCV post-transplant
increases access to HCV-positive donors, as HCV-positive livers
comprise 3% to 15% of donor pools across United Network for
Organ Sharing regions.35 Admittedly, this may be less of a clinical
concern given recent experiences with transplanting HCV-positive
organs into HCV-negative hosts. Consistent with prior literature, our
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study demonstrates initiating DAA therapy 0 to 3 months post-LT
was associated with high rates of SVR. Remarkably, among the 20
liver transplant centers included in this consortium, only a minority
of patients (10%) received DAAs 0 to 3 months post-LT. Although
postoperative complications may lead to a delay in initiating DAA
therapy, it is worth noting there was no significant difference in
postoperative complication rates between the DAA timing groups. In
fact, the postoperative complication rates were slightly higher in the
0 to 3 months post-LT group, compared to the pre-LT and 3 months
post-LT groups.
With the widespread use of DAAs, controversial data have
emerged suggesting an increased risk of recurrent HCC after DAA
therapy. Reig et al reported a high rate of early HCC recurrence of
35% in 20 patients treated with DAAs who underwent resection or
received liver-directed therapy.8 Comparably, 19 patients receiving
DAAs had an HCC recurrence rate of 42.1% in a study conducted by
Conti and colleagues.9 These findings may be confounded by a small
sample size and lack of a comparison group. More recent studies
have not observed an association between DAA administration and
HCC recurrence.10,36–41 A 2017 meta-analysis by Waziry et al
suggested there was no evidence for increased HCC recurrence after
SVR was achieved from DAA or interferon-based therapy, however,
the impact of timing of therapy as a variable was not taken into
consideration.11 The above conflicting literature highlight the significant heterogeneity of study inclusion criteria, HCC treatment
modalities, and HCV treatment regimens.
Currently, there is limited data regarding the optimal time to
initiate DAAs in the liver transplant population.42,43 A study by Gorgen
et al sought to answer this question among 516 patients with underwent
LT for HCV with concomitant HCC who received DAA therapy either
pre or post-LT.44 The investigators reported an SVR rate of 93.4% and a
5-year RFS of 93.4% for patients who received DAAs pre-LT and an
SVR rate of 96.5% and a recurrence rate of 2.9% for those who
received DAAs post-LT. However, the study time period included
patients from 2005 to 2015, while DAAs were only widely disseminated in 2015. In addition, a number of patients were transplanted
outside of Milan criteria (9.1% pre-LT, 17.2% post-LT) and the median
time interval between administration of DAAs and liver transplant was
2.4 months for pre-LT and 24 months post-LT. The comparison groups
also included patients who received interferon, a now outdated form of
treatment. Our study, in contrast, sought to determine the optimal
timing of DAA therapy in the modern era of HCV treatment in an
interferon treatment-naı̈ve patient population.
Limitations of this study include those inherent in a retrospective design, specifically the exclusion of missing data. Second,
the event rate for recurrence was zero for the patients who received
DAAs 0 to 3 months post-LT, limiting our ability to perform multivariable analysis, and the sample size was small in that timing group.
However, the fact that there were no events is very striking and
warrants further investigation. Third, as this study represents realworld practice patterns, there is variability between institutions
regarding DAA regimen, pre-LT therapy, post-LT immunosuppression, and surveillance protocols for HCC recurrence. Fourth, data on
specific HCV genotype was not available.
A major strength of this study is mitigation of single-institution or single-provider bias with a consortium of 20 transplant centers
in the US. Second, the isolation of our exposure of interest, the timing
of DAA therapy, was improved as a result of our selected inclusion
criteria for liver transplant patients with HCV-associated HCC who
were interferon treatment-naı̈ve and within Milan criteria. Thus, we
were able to limit potential biological confounders and better control
for immunologic and oncologic variability. Third, the rates of SVR
and RFS represent real-world data from among the highest volume
liver transplant centers in the US. Lastly, the findings of this study
618 | www.annalsofsurgery.com

provide clinicians with valuable insights that can be readily applied
to clinical practice, although further investigation into the immunologic mechanism is needed.

CONCLUSIONS
In summary, the optimal timing of DAA therapy appears to be
0 to 3 months after liver transplant for HCV-associated HCC, given
increased rates of SVR and improved HCC RFS. Importantly,
delayed administration of DAAs more than 3 months after liver
transplant should be avoided as it is possible that induction of
immunosuppression post-transplant in combination with prolonged
exposure to HCV and an exaggerated state of T cell impairment
created by the late administration of DAA therapy may lead to
increased HCC recurrence. A randomized prospective trial is warranted to validate these findings.
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DISCUSSANT
Dr. Robert A. Montgomery:
I want to thank the ASA and meeting organizers for inviting
me to comment on the paper entitled, ‘‘Optimal Timing of
Direct Acting Antivirals for Patients with Hepatitis C-Associated
HCC Undergoing LT’’ which was nicely presented by Dr. Michael
Turgeon.
The authors report data from the HCC LT Consortium looking
at the timing of DAA treatment among patients who underwent LT
between 2015 and 2019. The primary outcomes were sustained viral
response and 5-year HCC recurrence-free survival. The major finding was that the optimal timing for DAA therapy was 0-3 months
post-transplantation and delaying treatment beyond 3 months was
associated with worse outcomes.
Question #1 for the investigators is why were the overall SVR
rates lower than expected for pan-genotypic DAAs that have cited
cure rates exceeding 95%?
Question #2 when SVR was not achieved was there a dominant
genotype or DAA regimen associated with incomplete response?

Response Dr. Shishir K. Maithel
Thank you Drs. Deveney and Drebin. On behalf of all our coauthors, I would first like to thank the American Surgical for the
privilege of presenting our study today. It is also truly an honor to
have Dr. Montgomery review and comment on our paper. I would
also like to acknowledge Dr. Michael Turgeon, a general surgery
resident at Emory, for all of his hard work leading this large multiinstitutional study and thank Drs. Shimul Shah and Will Chapman for
co-leading this study with us.
I will first address Dr. Montgomery’s question regarding the
overall SVR rates being lower than expected. The 95% to 97% cure
rate that is often quoted is derived from studies that include patients
with HCV who do not have HCC. Patients with active HCC seem to
achieve significantly lower rates of SVR compared to non-HCC
patients. In fact, a recent meta-analysis published in 2019 by one of
our coauthors, Dr. Mindie Nguyen from Stanford University,
reported that the SVR rates with DAA therapy in the presence of
active HCC were as low as 73%. They also found that SVR rates were
higher in patients who underwent curative intent treatments of their
HCC before receiving DAA therapy. Although the exact mechanism
for this observation is not fully understood, HCC may function as a
reservoir for HCV replication. Further, the usual associated cirrhosis
that is present in patients who have HCV and HCC may lead to
impaired innate and adaptive immune responses due to reduced
cytotoxicity of natural killer cells and T cell exhaustion, leading
to suboptimal SVR rates in these patients.
With regards to the second question regarding genotypes, we
unfortunately did not have the granularity of specific genotypes in
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our database, so that is definitely a limitation of this study. Given the
time frame of our study from 2015 to 2019, 50% of the patients
received Harvoni. Since genotypes 1 and 2 comprise the vast majority
of HCV infections, despite Harvoni not having activity against
Genotype 3, which makes up only 10% to 12% of infections, the
SVR rate for Harvoni was 88%. Epclusa had an SVR rate of 94% and
interestingly Mavyret had the lowest SVR rate of 79%. Despite these
small differences in SVR rates between the 3 most common regimens, on binary logistic regression analysis, it is important to note
that no one regimen was significantly associated with a lower
SVR rate.
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Clearly, the interaction between HCV, HCC, post-transplant
immunosuppression, and DAA therapy is very complex and affects
both the success of DAA therapy in achieving SVR, and the success
of LT in achieving cure of HCC. Furthermore, achieving SVR seems
to also be associated with improved oncologic outcomes for HCC as
well. Thus, we strongly feel that the optimal timing of DAA therapy
needs to be studied in a prospective clinical trial and the underlying
immunologic mechanisms that drive these clinical observations need
to be studied and understood.
Again, thank you to the American Surgical Association for the
privilege of presenting our work today.
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